Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents

Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/57728

Title:	Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
Authors:	Linda Aurpibul Pagakrong Lumbiganon Rawiwan Hansudewechakul Suparat Kanjanavanit Torsak Bunupuradah Pope Kosalaraksa Pawinee Taeprasert Thanyawee Puthanakit
Authors:	Linda Aurpibul Pagakrong Lumbiganon Rawiwan Hansudewechakul Suparat Kanjanavanit Torsak Bunupuradah Pope Kosalaraksa Pawinee Taeprasert Thanyawee Puthanakit
Keywords:	Medicine
Issue Date:	1-Apr-2017
Abstract:	Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-human immunodeficiency virus-coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their median age was 17.6 years, and duration of 3TC exposure was 7.3 years. Eleven patients (61%) achieved HBV DNA <60 IU/mL after 48 weeks on TDF and 3TC which was similar to adult studies, although hepatitis B surface antigen loss or hepatitis B envelope antigen seroconversion did not occur.
URI:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85007247655&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/57728
ISSN:	15320987 08913668
Appears in Collections:	CMUL: Journal Articles

Files in This Item:

There are no files associated with this item.